Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
July 23, 2022 at 12:12 am IST
Share
Regen BioPharma, Inc. reported earnings results for the third quarter and nine months ended June 30, 2022. For the third quarter, the company reported sales was USD 0.058717 million compared to USD 0.056631 million a year ago. Revenue was USD 0.058717 million compared to USD 0.056631 million a year ago. Net income was USD 66.96 million compared to net loss of USD 7.49 million a year ago. Basic earnings per share from continuing operations was USD 19.1099 compared to basic loss per share from continuing operations of USD 3.15 a year ago.
For the nine months, sales was USD 0.176151 million compared to USD 0.11148 million a year ago. Revenue was USD 0.176151 million compared to USD 0.11148 million a year ago. Net income was USD 2.52 million compared to net loss of USD 5.38 million a year ago. Basic earnings per share from continuing operations was USD 0.75 compared to basic loss per share from continuing operations of USD 3 a year ago.
Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patientâs immune system through gene silencing of NR2F6.